Abstract
Uterine epithelial cancers are the most common type of gynecologic cancer in the United States. The American Cancer Society estimated 53,000 new cases of uterine cancers in 2014 with 8,600 deaths from advanced or recurrent cases, 99% of which are endometrial cancer. The 5-year survival rate of low-stage, low-grade endometrioid adenocarcinoma is greater than 90%. In contrast, advanced stage endometrioid adenocarcinomas and Type II (serous and carcinosarcoma) endometrial cancers have a much poorer prognosis, with the 5-year survival rate of advanced stage uterine carcinosarcoma as low as 9%. Together, these endometrial cancers with poor prognoses comprise almost half of all cases in the US, creating a significant medical obstacle for management. The authors present a review of endometrial cancer pathology, diagnosis and treatment. Included on the topic of treatment are: surgery, endocrine therapy, and chemotherapy with commentary on pertinent phase II and III clinical trials. The discussion covers single and multi-agent chemotherapy. Also covered are current clinical trials using targeted therapies such as mTOR inhibitors, angiokinase inhibitors, and HER2-directed agents. The review concludes with thoughts on future directions in therapeutic management of this disease.
Keywords: Endometrial cancer, endometrioid adenocarcinoma, serous, carcinosarcoma, chemotherapy, endocrine therapy, targeted therapy.
Current Cancer Therapy Reviews
Title:Treatment of Uterine Carcinomas
Volume: 11 Issue: 4
Author(s): Mary Chu, Estrelania Williams, D. Stave Kohtz, Tamara Kalir and David Fishman
Affiliation:
Keywords: Endometrial cancer, endometrioid adenocarcinoma, serous, carcinosarcoma, chemotherapy, endocrine therapy, targeted therapy.
Abstract: Uterine epithelial cancers are the most common type of gynecologic cancer in the United States. The American Cancer Society estimated 53,000 new cases of uterine cancers in 2014 with 8,600 deaths from advanced or recurrent cases, 99% of which are endometrial cancer. The 5-year survival rate of low-stage, low-grade endometrioid adenocarcinoma is greater than 90%. In contrast, advanced stage endometrioid adenocarcinomas and Type II (serous and carcinosarcoma) endometrial cancers have a much poorer prognosis, with the 5-year survival rate of advanced stage uterine carcinosarcoma as low as 9%. Together, these endometrial cancers with poor prognoses comprise almost half of all cases in the US, creating a significant medical obstacle for management. The authors present a review of endometrial cancer pathology, diagnosis and treatment. Included on the topic of treatment are: surgery, endocrine therapy, and chemotherapy with commentary on pertinent phase II and III clinical trials. The discussion covers single and multi-agent chemotherapy. Also covered are current clinical trials using targeted therapies such as mTOR inhibitors, angiokinase inhibitors, and HER2-directed agents. The review concludes with thoughts on future directions in therapeutic management of this disease.
Export Options
About this article
Cite this article as:
Chu Mary, Williams Estrelania, Stave Kohtz D., Kalir Tamara and Fishman David, Treatment of Uterine Carcinomas, Current Cancer Therapy Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573394712666151119213759
DOI https://dx.doi.org/10.2174/1573394712666151119213759 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on the Techniques for Characterizing and Predicting Human Genomic DNA Methylation
Current Bioinformatics Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy
Current Cancer Drug Targets Highlights on Medical Treatment of Uterine Fibroids
Current Pharmaceutical Design Meet the Editorial Board:
Current Drug Targets Reproductive Toxicology of Environmental Toxicants: Emerging Issues and Concerns
Current Pharmaceutical Design Diffusion-Weighted Imaging in Abdominal Oncology
Current Medical Imaging MMP-2 Selectivity in Hydroxamate-Type Inhibitors
Current Medicinal Chemistry Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis
Current Drug Targets Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Intraoperative Assessment of Myometrial Invasion in Endometrioid Adenocarcinoma
Current Women`s Health Reviews Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology Altered Steroid Metabolism and Insulin Signaling in PCOS Endometria: Impact in Tissue Function
Current Pharmaceutical Design Biomarkers for Cancers in Women: Present Status and Future Perspectives
Current Women`s Health Reviews Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism
Current Pharmaceutical Design Patented Biomarker Panels in Early Detection of Cancer
Recent Patents on Biomarkers